Alector, Inc. Reports Positive Safety Data in First-in-Human Study of Neurodegenerative Disease Therapeutic
Alector, Inc. (Nasdaq: ALEC), a clinical-stage immuno-neurology and immuno-oncology company, has reported positive safety and biomarker data from its first-in-human Phase 1 study of AL101, a potential treatment for neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. AL101 was well-tolerated and elevated progranulin levels in the cerebrospinal fluid of healthy volunteers.
- The study was a randomized, double-blind, placebo-controlled Phase 1 study in 88 healthy volunteers who received either single or multiple doses of AL101 administered intravenously or subcutaneously.
- The results pave the way for exploring multiple indications and dosing schedules for AL101.
- Progranulin is a key regulator of immune activity and lysosomal function in the brain.
- Even moderately reduced progranulin expression may lead to an increased risk of developing neurodegenerative disorders.
Alector’s study will test the hypothesis that increasing progranulin in the brain of patients suffering from neurodegenerative diseases may counteract disease pathology.